Despite significant increases in average life expectancy globally, the extension of healthy years—those free from chronic illnesses and age-related decline—has lagged. The prevalence of chronic diseases escalates sharply with age, posing immense challenges to healthcare systems and diminishing quality of life. The ARPA-H funded initiative seeks to disrupt this paradigm by transitioning from a reactive medical approach that treats diseases after their onset to a proactive strategy focused on prevention of biological aging and decline before clinical symptoms emerge.

Dr. Belsky, a key figure affiliated with Columbia’s Robert N. Butler Columbia Aging Center, emphasizes the urgent need for objective and measurable biological signals that can demonstrate the efficacy of interventions targeting the aging process itself. Identification of such biomarkers would enable clinicians and researchers to assess in real-time whether treatments genuinely decelerate aging, thereby preserving health, functional independence, and quality of life in aging populations.

The five-year PROSPR program supports a landmark project known as FAST—Facilitating Aging Studies with Translational data—which represents a paradigm shift in geriatric medicine. Unlike traditional clinical trials that often focus on singular diseases or symptoms, the FAST initiative integrates and analyzes existing clinical trial datasets and biospecimens relating to medications with known geroprotective properties. This meta-analytic approach allows for the discovery of novel biomarkers that capture the multifaceted biology of aging and identify effective interventions.

FAST incorporates data from trials involving four out of five key classes of drugs prioritized for their potential to modulate fundamental aging processes: metformin, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and rapamycin. These pharmacological agents have been shown in preclinical studies to extend lifespan by targeting cellular and molecular pathways implicated in aging such as metabolic regulation, inflammation, and cellular senescence. Their broad-spectrum benefits in humans beyond their original therapeutic indications highlight their promise as modulators of biological aging.

Preliminary findings from analyses within the FAST framework are particularly compelling. Evidence suggests that rapamycin administration can slow ovarian aging by approximately 20%, potentially prolonging female fertility by up to five years. Additional data indicate improvements in cardiovascular biomarkers, enhancements in patient-reported outcomes relating to overall health status, and a measurable deceleration in progression to type 2 diabetes mellitus. These early results underscore FAST’s vast potential to uncover clinically meaningful effects of aging-modifying drugs.

Andrew Brack, the ARPA-H Program Manager and architect of the PROSPR initiative, underscores the essential role of biomarkers in expediting clinical research on aging. Because the aging process spans decades, clinical trials must rely on surrogate endpoints that demonstrate early biological responses to interventions. FAST’s comprehensive database and multimodal analysis pipeline provide a transformative platform to identify and validate such biomarkers, bridging a critical gap in translational geroscience.

The FAST project’s success hinges on a multidisciplinary consortium spanning multiple top-tier research institutions. Expertise ranges from aging biology and clinical pharmacology to proteomics, metabolomics, epigenetics, biostatistics, and computational biology, enabling sophisticated integration and interpretation of clinical and molecular data. Dr. Belsky serves as principal investigator while co-leads include Dr. Nir Barzilai of Albert Einstein College of Medicine and Dr. Mahdi Moqri of Brigham and Women’s Hospital. Columbia’s Zohn Rosen manages the project logistics and coordination.

Dr. Barzilai highlights the transformative potential of FAST to redefine how aging is measured and managed clinically. The program envisions a future in which older adults undergo routine biological age assessments, receive tailored interventions, and observe tangible rejuvenation within months. Simultaneously, pharmaceutical innovators will leverage FAST’s biomarker toolkit to accelerate the development and regulatory approval of next-generation gerotherapeutics, fundamentally altering the trajectory of healthcare for aging populations.

All data generated by FAST will be securely housed and made accessible to qualified researchers through the Columbia Data Platform (CDP), a cutting-edge cloud infrastructure operated by Redivis on Google Cloud. This data-sharing paradigm fosters open collaboration and rapid scientific discovery, positioning FAST as a global hub for aging research innovation.

Dr. Belsky reflects on the paradigm shift catalyzed by this initiative: “FAST is moving the science of aging from theoretical frameworks and animal models into actionable human biology. By harnessing data from diverse clinical trials, we have the unprecedented opportunity to pinpoint the biological signals that truly slow aging in humans—and pivot medicine toward prevention rather than reaction.”

Moreover, the project signifies a critical inflection point in geroscience research. Rather than segmenting diseases for treatment, FAST confronts the challenge of aging as a complex, systemic process. This holistic perspective is poised to redefine clinical practice in aging societies by focusing on extending the duration of healthy, functional years, thereby reducing the burden of age-associated morbidity and healthcare costs.

Originally incubated by the American Federation for Aging Research and co-led by Drs. Belsky, Barzilai, and Moqri, the FAST project includes a network of collaborators at Columbia University such as Aris Floratos in Systems Biology, Yousin Suh in Obstetrics and Gynecology, Zhonghua Liu in Biostatistics, and Gary Miller in Environmental Health Sciences. Partner institutions include Duke University, Saint Luke’s Health System, and industry collaborators like NovoNordisk, OLink Proteomics, and TruDiagnostic Epigenetics, reflecting a broad coalition across academia, healthcare, and biotechnology.

Columbia University Mailman School of Public Health serves as the academic home for FAST, leveraging its century-old legacy of interdisciplinary research and global public health impact. The Robert N. Butler Columbia Aging Center similarly contributes an integrative framework combining biosocial insights with policy and practical applications to meet the demands of an aging demographic.

This project epitomizes a new frontier in public health and preventive medicine, wherein the biological mysteries of aging are decoded and harnessed to extend healthy human longevity. By redefining how aging-related decline is measured and treated, the FAST initiative promises to usher in an era where living longer is accompanied by living better—free from the disabilities and chronic conditions that have long shadowed extra years of life.

Subject of Research: Biological hallmarks of aging; development and validation of biomarkers to measure and intervene upon the aging process in humans.

Article Title: Accelerating Healthy Aging: Columbia University’s FAST Initiative Harnesses Clinical Trial Data to Transform Geroscience

News Publication Date: February 24, 2026

Web References:
– Columbia University Mailman School of Public Health: www.mailman.columbia.edu
– Robert N. Butler Columbia Aging Center: aging.columbia.edu
– ARPA-H PROSPR Program: [Link to official ARPA-H PROSPR program site, if available]

Keywords: Aging biology, biomarkers, geroscience, clinical trials, metformin, rapamycin, SGLT-2 inhibitors, GLP-1 agonists, public health, preventive medicine, longevity, chronic disease prevention

The impetus behind invigorating biomarker discovery springs from an urgent clinical and societal need. Chronological age alone is insufficient in capturing the heterogeneity of aging among individuals. Biological age—an aggregate reflection of physiological decline and damage accumulation—requires robust, reliable, and clinically actionable biomarkers that can forecast disease risk, track therapeutic interventions, and ultimately guide personalized health strategies. Jacques et al. embark on this challenge by synthesizing interdisciplinary methodologies that transcend traditional markers, such as telomere length or inflammatory profiles, moving toward integrative molecular signatures with enhanced sensitivity and specificity.

Central to their approach is the deployment of high-throughput multi-omics technologies, encompassing genomics, epigenomics, transcriptomics, proteomics, and metabolomics. By integrating data streams from these diverse but complementary domains, the researchers have crafted composite biomarker profiles that capture systemic aging processes at multiple biological scales. Their analytical pipeline employs sophisticated machine learning algorithms capable of disentangling age-related signals from confounding variables such as lifestyle, environmental exposures, and comorbidities. This computational rigor ensures biomarker robustness, reproducibility across cohorts, and adaptability for diverse populations.

One of the pivotal innovations highlighted in the research is the refinement of epigenetic clocks. While earlier models based on DNA methylation patterns offered promising age-prediction accuracy, Jacques and colleagues have enhanced these clocks by incorporating novel CpG sites linked to mechanistic aging pathways, including cellular senescence and DNA damage response. These advanced clocks demonstrate superior predictive power not only for chronological age but also for biological functions, such as immune competence and regenerative capacity, thereby bridging the gap between molecular measurements and physiological outcomes.

Beyond identifying biomarkers, the study tackles the equally challenging task of clinical translation. The authors underscore the necessity of standardizing biomarker assays for routine use, emphasizing scalability, cost-effectiveness, and minimal invasiveness. For instance, they report progress toward blood-based biomarker panels that require only small volumes of plasma or serum, facilitating integration into regular health assessments. Moreover, by correlating biomarker dynamics with longitudinal clinical data, the research delineates how these molecular indices can forecast onset and progression of age-related diseases such as cardiovascular disorders, neurodegeneration, and metabolic syndrome.

A particularly compelling aspect of this work is the exploration of biomarkers’ utility in monitoring the efficacy of geroprotective interventions. By quantifying biological age changes in response to therapeutic strategies—ranging from caloric restriction mimetics and senolytics to physical exercise regimens—the study paves the way for adaptive and personalized aging management. This paradigm shift moves geriatrics from a reactive to a proactive discipline, leveraging molecular insights to delay or even reverse deleterious aging trajectories.

The implications of this research also extend to drug development pipelines, where validated aging biomarkers can serve as surrogate endpoints in clinical trials. This innovation holds promise to expedite evaluation of candidate compounds, mitigate costs, and improve regulatory pathways. With aging recognized increasingly as a modifiable risk factor, regulatory agencies have shown growing interest in biomarker-guided approvals, making the findings by Jacques et al. not merely academic but poised to influence health policy and pharmaceutical innovation.

Another critical dimension addressed is the ethical and societal implications of implementing aging biomarkers. The authors advocate for responsible deployment, cautioning against potential misuse, such as discrimination in insurance or employment based on biological age. They call for establishing frameworks that ensure equitable access and safeguard individual privacy, underscoring that the technological sophistication of biomarker tools must be matched with ethical stewardship.

In supporting the reproducibility and transparency of their work, Jacques and colleagues have provided open-source computational tools and extensive datasets from diverse cohorts, enhancing collaborative efforts worldwide. This openness fosters cross-validation and refinement by independent research groups, accelerating collective advancement. The study’s multi-institutional collaboration exemplifies the power of integrating expertise across molecular biology, bioinformatics, clinical sciences, and ethics.

Technological evolution remains integral to future advances. The authors speculate on emerging modalities such as single-cell multi-omics, spatial transcriptomics, and deep phenotyping to deepen biomarker precision, uncovering cellular heterogeneity and tissue-specific aging patterns. Coupled with wearable sensors and digital health platforms, there is potential to blend molecular aging metrics with real-time physiological data, creating dynamic models of aging that guide timely interventions.

Importantly, the publication situates these scientific breakthroughs within the broader context of population health. Aging biomarkers could revolutionize epidemiological monitoring, enabling public health officials to identify at-risk subpopulations and tailor preventive measures accordingly. This precision public health approach could alleviate burdens on healthcare systems by shifting focus from disease treatment to health span extension.

Despite these strides, challenges remain. The complexity of aging, influenced by genetic, epigenetic, environmental, and stochastic factors, demands biomarkers that reflect this multifactorial nature. The study acknowledges the need for continued validation across different ethnicities, sexes, and socioeconomic backgrounds to ensure universal applicability and avoid exacerbating health disparities.

In summary, Jacques, Herzog, Ying, and colleagues deliver a masterful and comprehensive examination of aging biomarker discovery and translation, offering an unprecedented toolkit for unlocking the mysteries of aging. Their integrated multi-omics strategies, combined with rigorous computational models and translational foresight, set a new standard for geroscience research. As the field moves toward clinical reality, this work heralds a future where biological age is quantifiable, modifiable, and harnessed to enhance human health and longevity.

This publication represents a milestone not only in aging research but also in personalized medicine. By facilitating early detection of aging-related pathologies and enabling individualized therapeutic regimens, these advances promise to transform healthcare paradigms. The capacity to measure and modulate the aging process could redefine concepts of disease, wellness, and lifespan itself.

The scientific community eagerly anticipates further validation studies and the rollout of biomarker-guided clinical trials inspired by this work. Ultimately, the confluence of molecular biology, data science, and clinical innovation in this study illuminates a path toward achieving healthy aging at scale, a goal of profound human and societal significance.

Subject of Research:
Discovery and clinical translation of biomarkers for aging.

Article Title:
Invigorating discovery and clinical translation of aging biomarkers.

Article References:
Jacques, E., Herzog, C., Ying, K. et al. Invigorating discovery and clinical translation of aging biomarkers. Nat Aging 5, 539–543 (2025). https://doi.org/10.1038/s43587-025-00838-w

Image Credits:
AI Generated